Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abrahamsen, 2004, TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling, J Immunol, 173, 4847, 10.4049/jimmunol.173.8.4847
Ahn, 1997, Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity, J Med Chem, 40, 2196, 10.1021/jm9608467
Alexander, 2002, A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors, Bioorg Med Chem Lett, 12, 1451, 10.1016/S0960-894X(02)00202-0
Andreeva, 2001, Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain, J Neurosci, 21, 9068, 10.1523/JNEUROSCI.21-22-09068.2001
Artemyev, 1996, Subunit structure of rod cGMP-phosphodiesterase, J Biol Chem, 271, 25382, 10.1074/jbc.271.41.25382
Asano, 1997, Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors, Mol Pharmacol, 13, 400
Ashman, 1963, Isolation of adenosine 3′, 5′-monophosphate and guanosine 3′, 5′-monophosphate from rat urine, Biochem Biophys Res Commun, 11, 330, 10.1016/0006-291X(63)90566-7
Asirvatham, 2004, A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines, J Immunol, 173, 4806, 10.4049/jimmunol.173.8.4806
Auerbach, 1974, A simple procedure for the long-term cultivation of chicken embryos, Dev Biol, 41, 391, 10.1016/0012-1606(74)90316-9
Baecker, 1994, Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD), Gene, 138, 253, 10.1016/0378-1119(94)90818-4
Baillie, 2003, Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi, Proc Natl Acad Sci U S A, 100, 940, 10.1073/pnas.262787199
Barber, 2004, Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers, Am J Physiol Lung Cell Mol Physiol, 287, L332, 10.1152/ajplung.00384.2003
Barnette, 1995, Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site, J Pharmacol Exp Ther, 273, 1396
Barnette, 1995, The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity, J Pharmacol Exp Ther, 273, 674
Beard, 2000, UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions, J Biol Chem, 275, 10349, 10.1074/jbc.275.14.10349
Beavo, 1995, Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms, Physiol Rev, 75, 725, 10.1152/physrev.1995.75.4.725
Beavo, 1971, Stimulation of adenosine 3′,5′-monophosphate hydrolysis by guanosine 3′,5′-monophosphate, J Biol Chem, 246, 3841, 10.1016/S0021-9258(18)62110-6
Bender, 2004, Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression, Cell Signal, 16, 365, 10.1016/j.cellsig.2003.08.009
Bentley, 2001, Nerve growth factor inhibits PC12 cell PDE 2 phosphodiesterase activity and increases PDE 2 binding to phosphoproteins, J Neurochem, 76, 1252, 10.1046/j.1471-4159.2001.00133.x
Bergstrand, 1977, Effects of antiallergic agents, compound 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate phosphodiesterases, Mol Pharmacol, 13, 38
Billah, 2002, Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor, J Pharmacol Exp Ther, 302, 127, 10.1124/jpet.302.1.127
Bloom, 1996, Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants, Proc Natl Acad Sci U S A, 93, 14188, 10.1073/pnas.93.24.14188
Boess, 2004, Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance, Neuropharmacology, 47, 1081, 10.1016/j.neuropharm.2004.07.040
Boichot, 2000, Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine, J Pharmacol Exp Ther, 292, 647
Bolger, 1993, A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs, Mol Cell Biol, 13, 6558, 10.1128/MCB.13.10.6558
Boolell, 1996, Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int J Impot Res, 8, 47
Bourguignon, 1997, 9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors, J Med Chem, 40, 1768, 10.1021/jm960827x
Bourtchouladze, 2003, Mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4, Proc Natl Acad Sci U S A, 100, 10518, 10.1073/pnas.1834280100
Bristol, 1984, Cardiotonic agents: 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure, J Med Chem, 27, 1099, 10.1021/jm00375a001
Brunkhorst, 1989, Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart, Naunyn Schmiedebergs Arch Pharmacol, 339, 575, 10.1007/BF00167264
Butcher, 1962, Adenosine 3′, 5′-phosphate in biological materials: 1. Purification and properties of cyclic 3′, 5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′, 5′-phosphate in human urine, J Biol Chem, 237, 1244, 10.1016/S0021-9258(18)60316-3
Buxton, 1983, Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes, J Biol Chem, 258, 10233, 10.1016/S0021-9258(17)44447-4
Chabre, 1988, Visual signal transduction: the cycle of transducin shuttling between rhodopsin and cGMP phosphodiesterase, Cold Spring Harb Symp Quant Biol, 1, 313, 10.1101/SQB.1988.053.01.038
Charbonneau, 1990, Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases, Proc Natl Acad Sci U S A, 87, 288, 10.1073/pnas.87.1.288
Chasin, 1976, Inhibitory and activators of cyclic nucleotide phosphodiesterase, Adv Cycl Nucleotide Res, 7, 225
Cheung, 1970, Cyclic 3′,5′-nucleotide phosphodiesterase. Demonstration of an activator, Biochem Biophys Res Commun, 38, 533, 10.1016/0006-291X(70)90747-3
Cheung, 1996, Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis, Blood, 88, 1321, 10.1182/blood.V88.4.1321.bloodjournal8841321
Christensen, 1998, 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma, J Med Chem, 41, 821, 10.1021/jm970090r
Claveau, 2004, Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor, J Pharmacol Exp Ther, 310, 752, 10.1124/jpet.103.064691
Conti, 2000, Phosphodiesterases and cyclic nucleotide signaling in endocrine cells, Mol Endocrinol, 14, 1317, 10.1210/me.14.9.1317
Conti, 1995, Characterization of a hormone-inducible, high affinity adenosine 3′-5′-cyclic monophosphate phosphodiesterase from the rat Sertoli cell, Biochemistry, 34, 7979, 10.1021/bi00025a003
Conti, 2003, Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling, J Biol Chem, 278, 5493, 10.1074/jbc.R200029200
Cook, 1987, Identification, purification, and functional reconstitution of the cyclic GMP-dependent channel from rod photoreceptors, Proc Natl Acad Sci U S A, 84, 585, 10.1073/pnas.84.2.585
Coquil, 1975, Cyclic nucleotide phosphodiesterase of retinal photoreceptors. Partial purification and some properties of the enzyme, Biochim Biophys Acta, 403, 425, 10.1016/0005-2744(75)90070-4
Coquil, 1980, Characteristics of a new binding protein distinct from the kinase for guanosine 3′:5′-monophosphate in rat platelets, Biochim Biophys Acta, 631, 148, 10.1016/0304-4165(80)90063-X
Corbin, 2000, Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities, Eur J Biochem, 267, 2760, 10.1046/j.1432-1327.2000.01297.x
Coste, 1995, Characterization of a novel potent and specific inhibitor of type V phosphodiesterase, Biochem Pharmacol, 50, 1577, 10.1016/0006-2952(95)02031-4
Cote, 2004, Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5, Int J Impot Res, 16, S28, 10.1038/sj.ijir.3901212
Coudray, 1999, Evidence for the presence of several phosphodiesterase isoforms in brown adipose tissue of Zucker rats: modulation of PDE2 by the fa gene expression, FEBS Lett, 456, 207, 10.1016/S0014-5793(99)00934-5
Cruickshank, 1993, Phosphodiesterase III inhibitors: long-term risks and short-term benefits, Cardiovasc Drugs Ther, 7, 655, 10.1007/BF00877818
D'Amours, 1999, Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme, Mol Pharmacol, 55, 508
Daugan, 2003, The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues, J Med Chem, 46, 4533, 10.1021/jm0300577
Degerman, 1987, Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand, J Biol Chem, 262, 5797, 10.1016/S0021-9258(18)45645-1
Degerman, 1990, Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation, Proc Natl Acad Sci U S A, 87, 533, 10.1073/pnas.87.2.533
de Rooij, 1998, Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP, Nature, 396, 474, 10.1038/24884
Dodge, 2001, mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module, EMBO J, 20, 1921, 10.1093/emboj/20.8.1921
Draheim, 2004, Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations, J Pharmacol Exp Ther, 308, 555, 10.1124/jpet.103.059097
Eckly, 1994, Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway, Br J Pharmacol, 113, 445, 10.1111/j.1476-5381.1994.tb17009.x
Eckly-Michel, 1997, Chelerythrine, a protein kinase C inhibitor, interacts with cyclic nucleotide phosphodiesterases, Eur J Pharmacol, 324, 85, 10.1016/S0014-2999(97)00149-0
Eckly-Michel, 1997, Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation, Br J Pharmacol, 122, 158, 10.1038/sj.bjp.0701339
Eddahibi, 1998, Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats, Br J Pharmacol, 125, 681, 10.1038/sj.bjp.0702124
Edmondson, 2003, Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors, Bioorg Med Chem, 13, 3983, 10.1016/j.bmcl.2003.08.056
Engels, 1995, Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C), FEBS Lett, 358, 305, 10.1016/0014-5793(94)01460-I
Epstein, 1982, Interaction of calcium antagonists with cyclic AMP phosphodiesterases and calmodulin, Biochem Biophys Res Commun, 105, 1142, 10.1016/0006-291X(82)91089-0
Erneux, 1981, Specificity of cyclic GMP activation of a multi-substrate cyclic nucleotide phosphodiesterase from rat liver, Eur J Biochem, 115, 503, 10.1111/j.1432-1033.1981.tb06231.x
Favot, 2003, VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors, Thromb Haemost, 90, 334, 10.1160/TH03-02-0084
Favot, 2004, Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4, Thromb Haemost, 92, 634, 10.1160/TH03-12-0768
Fawcett, 2000, Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A, Proc Natl Acad Sci U S A, 97, 3702, 10.1073/pnas.050585197
Fidock, 2002, Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants, Cell Signal, 14, 53, 10.1016/S0898-6568(01)00207-8
Fischmeister, 1990, Regulation of calcium current by low-Km cyclic AMP phosphodiesterases in cardiac cells, Mol Pharmacol, 38, 426
Fisher, 1998, Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase, Biochem Biophys Res Commun, 246, 570, 10.1006/bbrc.1998.8684
Fisher, 1998, Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase, J Biol Chem, 273, 15559, 10.1074/jbc.273.25.15559
Florio, 1996, Solubilization of membrane-bound rod phosphodiesterase by the rod phosphodiesterase recombinant delta subunit, J Biol Chem, 271, 24036, 10.1074/jbc.271.39.24036
Forte, 1992, Stimulation of intestinal Cl-transport by heat-stable enterotoxin: activation of cAMP-dependent protein kinase by cGMP, Am J Physiol, 263, C607, 10.1152/ajpcell.1992.263.3.C607
Francis, 1988, Purification of cGMP-binding protein phosphodiesterase from rat lung, Methods Enzymol, 159, 722, 10.1016/0076-6879(88)59067-5
Francis, 1999, Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action, Crit Rev Clin Lab Sci, 36, 275, 10.1080/10408369991239213
Francis, 1980, Characterization of a novel cGMP binding protein from rat lung, J Biol Chem, 255, 620, 10.1016/S0021-9258(19)86221-X
Francis, 2001, Cyclic nucleotide phosphodiesterases: relating structure and function, Prog Nucleic Acid Res Mol Biol, 65, 1, 10.1016/S0079-6603(00)65001-8
Francis, 2002, Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity, J Biol Chem, 277, 47581, 10.1074/jbc.M206088200
Fujishige, 1999, Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A), J Biol Chem, 274, 18438, 10.1074/jbc.274.26.18438
Fujishige, 2000, The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains, Eur J Biochem, 267, 5943, 10.1046/j.1432-1327.2000.01661.x
Gale, 2002, Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers, Br J Clin Pharmacol, 54, 478, 10.1046/j.1365-2125.2002.01682.x
Gardner, 2000, Related Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase, Biochem Biophys Res Commun, 272, 186, 10.1006/bbrc.2000.2743
Geoffroy, 1999, Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction, Eur J Biochem, 259, 892, 10.1046/j.1432-1327.1999.00123.x
Geoffroy, 2001, Characterization of an in vivo hormonally regulated phosphodiesterase 3 (PDE3) associated with a liver Golgi-endosomal fraction, Arch Biochem Biophys, 387, 154, 10.1006/abbi.2000.2252
Georget, 2003, Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8), FASEB J, 17, 1380, 10.1096/fj.02-0784com
Gillespie, 1989, Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948, Mol Pharmacol, 36, 773
Giordano, 1999, cAMP-dependent induction of PDE5 expression in murine neuroblastoma cell differentiation, FEBS Lett, 446, 218, 10.1016/S0014-5793(99)00227-6
Giordano, 2001, Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain, Biochim Biophys Acta, 1539, 16, 10.1016/S0167-4889(01)00086-6
Giorgi, 2002, Differential expression and localization of calmodulin-dependent phosphodiesterase genes during ontogenesis of chick dorsal root ganglion, J Neurochem, 80, 970, 10.1046/j.0022-3042.2002.00786.x
Glavas, 2001, T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3, Proc Natl Acad Sci U S A, 98, 6319, 10.1073/pnas.101131098
Gong, 2004, Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment, J Clin Invest, 114, 1624, 10.1172/JCI22831
Goraya, 2004, Sustained entry of Ca2+ is required to activate Ca2+ calmodulin-dependent phosphodiesterase 1A (PDE1A), J Biol Chem, 279, 40494, 10.1074/jbc.M313441200
Goridis, 1974, Light-regulated guanosine 3′,5′-monophosphate phosphodiesterase of bovine retina, Nature, 248, 57, 10.1038/248057a0
Gresser, 2002, Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil—review of the literature, Eur J Med Res, 7, 435
Guay, 2002, Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor, Bioorg Med Chem Lett, 12, 1457, 10.1016/S0960-894X(02)00190-7
Guipponi, 1998, Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence, Hum Genet, 103, 386, 10.1007/s004390050838
Gustafsson, 2002, Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1beta and NO: role of cGMP-stimulated PDE2, Am J Physiol Cell Physiol, 283, C463, 10.1152/ajpcell.00299.2001
Hagiwara, 1984, Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle, Biochem Pharmacol, 33, 453, 10.1016/0006-2952(84)90240-5
Hamet, 1978, Cyclic GMP binding and cyclic GMP phosphodiesterase in rat platelets, J Cycl Nucleotide Res, 4, 281
Hamilton, 1990, A phosphodiesterase inhibitor specific to a subset of bovine retinal cones, J Biol Chem, 265, 11259, 10.1016/S0021-9258(19)38585-0
Han, 1997, Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart, J Biol Chem, 272, 16152, 10.1074/jbc.272.26.16152
Han, 1999, The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion, J Biol Chem, 274, 22337, 10.1074/jbc.274.32.22337
Hansen, 2000, Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D, Proc Natl Acad Sci U S A, 97, 6751, 10.1073/pnas.97.12.6751
Hanson, 1998, Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message, Am J Respir Crit Care Med, 158, 279, 10.1164/ajrccm.158.1.9711042
Hanson, 1998, Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity, Am J Physiol, 275, L931
Harndahl, 2004, Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology, J Biol Chem, 279, 15214, 10.1074/jbc.M308952200
Harris, 1989, Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor, J Pharmacol Exp Ther, 249, 394
Harrison, 1986, Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs, Mol Pharmacol, 29, 506
Hartzell, 1986, Opposite effects of cyclic GMP and cyclic AMP on Ca2+ current in single heart cells, Nature, 323, 273, 10.1038/323273a0
Hashimoto, 1989, Regulation of Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase by the autophosphorylated form of Ca2+/calmodulin-dependent protein kinase II, J Biol Chem, 264, 10884, 10.1016/S0021-9258(18)81703-3
Haslam, 1999, Cyclic nucleotides and phosphodiesterases in platelets, Thromb Haemost, 82, 412, 10.1055/s-0037-1615861
Hatzelmann, 2001, Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro, J Pharmacol Exp Ther, 297, 267
Hayashi, 1998, Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase, Biochem Biophys Res Commun., 250, 751, 10.1006/bbrc.1998.9379
Hayashi, 2000, Phosphorylation by cyclin-dependent protein kinase 5 of the regulatory subunit of retinal cGMP phosphodiesterase: II. Its role in the turnoff of phosphodiesterase in vivo, J Biol Chem, 275, 32958, 10.1074/jbc.M000703200
Hayashi, 2002, Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene, Biochem Biophys Res Commun, 297, 1253, 10.1016/S0006-291X(02)02371-9
Haynes, 1996, Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3′,5′-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung, J Pharmacol Exp Ther, 276, 752
He, 1998, Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3), Cell Biochem Biophys, 29, 89, 10.1007/BF02737830
Hebb, 2004, Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of neuroscience, Neuroscience, 123, 967, 10.1016/j.neuroscience.2003.11.009
Hetman, 2000, Cloning and characterization of two splice variants of human phosphodiesterase 11A, Proc Natl Acad Sci U S A, 97, 12891, 10.1073/pnas.200355397
Hibert, 1988, Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor, J Med Chem, 31, 1087, 10.1021/jm00401a007
Hibert, 1991, Three-dimensional models of neurotransmitter G-binding protein-coupled receptors, Mol Pharmacol, 40, 8
Hidaka, 1979, Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation, J Pharmacol Exp Ther, 211, 26
Ho, 2000, Structure of the GAF domain, a ubiquitous signaling motif and a new class of cyclic GMP receptor, EMBO J, 19, 5288, 10.1093/emboj/19.20.5288
Houslay, 2003, PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization, Biochem J, 370, 1, 10.1042/bj20021698
Houslay, 1998, The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions, Adv Pharmacol, 44, 225, 10.1016/S1054-3589(08)60128-3
Hu, 2004, Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A, Eur J Neurosci, 20, 3351, 10.1111/j.1460-9568.2004.03796.x
Huai, 2003, The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis, Biochemistry, 42, 13220, 10.1021/bi034653e
Huai, 2004, Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity, J Biol Chem, 279, 13095, 10.1074/jbc.M311556200
Huang, 1981, Mechanism of activation of cyclic nucleotide phosphodiesterase: requirement of the binding of four Ca2+ to calmodulin for activation, Proc Natl Acad Sci U S A, 78, 871, 10.1073/pnas.78.2.871
Huang, 2004, Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase, J Biol Chem, 279, 48143, 10.1074/jbc.M404338200
Huston, 2000, The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution, J Biol Chem, 275, 28063, 10.1074/jbc.M906144199
Ichimura, 1993, A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines, Biochem Biophys Res Commun, 193, 985, 10.1006/bbrc.1993.1722
Ichimura, 1996, KS-505a, an isoform-selective inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase, Biochem J, 316, 311, 10.1042/bj3160311
Ilan, 1998, Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis, J Cell Sci, 111, 3621, 10.1242/jcs.111.24.3621
Iona, 1998, Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain, Mol Pharmacol, 53, 23, 10.1124/mol.53.1.23
Jacobitz, 1996, Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding, Mol Pharmacol, 50, 891
Jiang, 1992, Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries, J Biol Chem, 267, 1015, 10.1016/S0021-9258(18)48388-3
Jiang, 1996, Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells, Proc Natl Acad Sci U S A, 93, 11236, 10.1073/pnas.93.20.11236
Jin, 2002, Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses, Proc Natl Acad Sci U S A, 99, 7628, 10.1073/pnas.122041599
Jin, 1999, Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice, Proc Natl Acad Sci U S A, 96, 11998, 10.1073/pnas.96.21.11998
Juilfs, 1997, A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway, Proc Natl Acad Sci U S A, 94, 3388, 10.1073/pnas.94.7.3388
Jurevicius, 1996, cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists, Proc Natl Acad Sci U S A, 93, 295, 10.1073/pnas.93.1.295
Kajimura, 2002, Three-dimensional structure of non-activated cGMP phosphodiesterase 6 and comparison of its image with those of activated forms, J Struct Biol, 139, 27, 10.1016/S1047-8477(02)00502-6
Kakiuchi, 1970, Calcium dependent phosphodiesterase activity and its activating factor (PAF) from brain studies on cyclic 3′,5′-nucleotide phosphodiesterase (3), Biochem Biophys Res Commun, 41, 1104, 10.1016/0006-291X(70)90199-3
Kakkar, 1999, Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1), Cell Mol Life Sci, 55, 1164, 10.1007/s000180050364
Kameni-Tcheudji, 2001, Molecular organization of bovine rod cGMP-phosphodiesterase 6, J Mol Biol, 310, 781, 10.1006/jmbi.2001.4813
Kanda, 2001, Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells, Biochem Pharmacol, 62, 495, 10.1016/S0006-2952(01)00688-8
Keely, 1977, Involvement of cAMP-dependent protein kinase regulation of heart contractile force, Am J Physiol, 233, H269
Keravis, 2000, Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes, J Vasc Res, 37, 235, 10.1159/000025738
Kessler, 1995, Rolipram increases cyclic GMP content in l-arginine-treated cultured bovine aortic endothelial cells, Eur J Pharmacol, 290, 163, 10.1016/0922-4106(95)90030-6
Kim, 2001, Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance, Circulation, 104, 2338, 10.1161/hc4401.098432
Kimura, 2003, PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers, Hypertension, 41, 1106, 10.1161/01.HYP.0000068202.42431.CC
Kitamura, 1999, Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt, Mol Cell Biol, 19, 6286, 10.1128/MCB.19.9.6286
Kobayashi, 2003, Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain, Gene, 319, 21, 10.1016/S0378-1119(03)00809-6
Komas, 1989, Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues, J Cardiovasc Pharmacol, 14, 213, 10.1097/00005344-198908000-00005
Komas, 1991, Cardiac cGMP-stimulated cyclic nucleotide phosphodiesterases: effects of cGMP analogues and drugs, Eur J Pharmacol, 206, 5, 10.1016/0922-4106(91)90140-D
Komas, 1991, Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors, Br J Pharmacol, 104, 495, 10.1111/j.1476-5381.1991.tb12457.x
Kotera, 1998, Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase, J Biol Chem, 273, 26982, 10.1074/jbc.273.41.26982
Kotera, 1999, Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP, Biochem Biophys Res Commun, 261, 551, 10.1006/bbrc.1999.1013
Kotera, 2004, Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation, J Biol Chem, 279, 4366, 10.1074/jbc.M308471200
Koyanagi, 1998, Ancient gene duplication and domain shuffling in the animal cyclic nucleotide phosphodiesterase family, FEBS Lett, 436, 323, 10.1016/S0014-5793(98)01150-8
Kukovetz, 1970, Inhibition of cyclic-3′,5′-nucleotide-phosphodiesterase as a possible mode of action of papaverine and similarly acting drugs, Naunyn Schmiedebergs Arch Pharmacol, 267, 189, 10.1007/BF00999402
Kurtz, 1998, Stimulation of renin secretion by nitric oxide is mediated by phosphodiesterase 3, Proc Natl Acad Sci U S A, 95, 4743, 10.1073/pnas.95.8.4743
Laliberté, 2000, Conformational difference between PDE4 apoenzyme and holoenzyme, Biochemistry, 39, 6449, 10.1021/bi992432w
Lee, 2002, Crystal structure of phosphodiesterase 4D and inhibitor complex(1), FEBS Lett, 530, 53, 10.1016/S0014-5793(02)03396-3
Lee, 2002, PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP, Cell Signal, 14, 277, 10.1016/S0898-6568(01)00250-9
Lefièvre, 2002, Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa, Biol Reprod, 67, 423, 10.1095/biolreprod67.2.423
Li, 1990, Bovine cone photoreceptor cGMP phosphodiesterase structure deduced from a cDNA clone, Proc Natl Acad Sci U S A, 87, 293, 10.1073/pnas.87.1.293
Li, 1998, Characterization of human and mouse rod cGMP phosphodiesterase delta subunit (PDE6D) and chromosomal localization of the human gene, Genomics, 49, 76, 10.1006/geno.1998.5210
Li, 1999, CD3- and CD28-dependent induction of PDE7 required for T cell activation, Science, 283, 848, 10.1126/science.283.5403.848
Lin, 2001, Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site, Biochem Biophys Res Commun, 280, 693, 10.1006/bbrc.2000.4221
Lin, 2002, Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters, Int J Impot Res, 14, 15, 10.1038/sj.ijir.3900802
Lin, 2003, Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism, J Urol, 170, S15, 10.1097/01.ju.0000075500.11519.e8
Lipkin, 1990, Beta-subunit of bovine rod photoreceptor cGMP phosphodiesterase. Comparison with the phosphodiesterase family, J Biol Chem, 265, 12955, 10.1016/S0021-9258(19)38252-3
Liu, 1999, Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting, J Biol Chem, 274, 10557, 10.1074/jbc.274.15.10557
Liu, 2001, Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors, Biochemistry, 40, 10179, 10.1021/bi010096p
Liu, 2001, Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake, Cardiovasc Drug Rev, 19, 369, 10.1111/j.1527-3466.2001.tb00076.x
Livi, 1990, Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase, Mol Cell Biol, 10, 2678, 10.1128/MCB.10.6.2678
Lochhead, 1997, The regulation of the cGMP-binding cGMP phosphodiesterase proteins that are immunologically related to gamma subunit of the photoreceptor cGMP phosphodiesterase, J Biol Chem, 272, 18397, 10.1074/jbc.272.29.18397
Loughney, 1996, Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases, J Biol Chem, 271, 796, 10.1074/jbc.271.2.796
Loughney, 1998, Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase, Gene, 216, 139, 10.1016/S0378-1119(98)00303-5
Loughney, 1999, Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide, Gene, 234, 109, 10.1016/S0378-1119(99)00171-7
Lugnier, 2005, Phosphodiesterase methods and protocols, vol. 307
Lugnier, 1993, Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation, Eur Heart J, 14, 141
Lugnier, 1990, Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells, Biochem Pharmacol, 39, 75, 10.1016/0006-2952(90)90650-A
Lugnier, 1972, Cyclic nucleotide phosphodiesterase inhibition and vascular smooth muscle relaxation, Eur J Pharmacol, 19, 134, 10.1016/0014-2999(72)90090-8
Lugnier, 1983, Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity, Biochem Biophys Res Commun, 113, 954, 10.1016/0006-291X(83)91091-4
Lugnier, 1984, Bepridil and flunarizine as calmodulin inhibitors, Eur J Pharmacol, 98, 157, 10.1016/0014-2999(84)90128-6
Lugnier, 1986, Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta, Biochem Pharmacol, 35, 1743, 10.1016/0006-2952(86)90333-3
Lugnier, 1992, Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities, Am J Physiol, 262, H654
Lugnier, 1993, Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions, J Pharmacol Exp Ther, 265, 1142
Lugnier, 1999, Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel, J Physiol Pharmacol, 50, 639
Lugnier, 1999, Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei, Biochim Biophys Acta, 1472, 431, 10.1016/S0304-4165(99)00145-2
MacFarland, 1991, High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells, J Biol Chem, 266, 136, 10.1016/S0021-9258(18)52413-3
MacKenzie, 2000, ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions, J Biol Chem, 275, 16609, 10.1074/jbc.275.22.16609
Macphee, 1986, Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents, Proc Natl Acad Sci U S A, 83, 6660, 10.1073/pnas.83.17.6660
Manganiello, 1990, Cyclic-GMP-stimulated cyclic nucleotide phosphodiesterases, 61
Manning, 1996, Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B, J Pharmacol Exp Ther, 276, 810
Manning, 1999, Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B, Br J Pharmacol, 128, 1393, 10.1038/sj.bjp.0702911
Marivet, 1989, Inhibition of cyclic adenosine-3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues, J Med Chem, 32, 1450, 10.1021/jm00127a009
Martin, 1986, Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor, J Pharmacol Exp Ther, 237, 539
Martinez, 2002, The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding, Proc Natl Acad Sci U S A, 99, 13260, 10.1073/pnas.192374899
Martins, 1982, Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues, J Biol Chem, 257, 1973, 10.1016/S0021-9258(19)68134-2
Masciarelli, 2004, Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility, J Clin Invest, 114, 196, 10.1172/JCI21804
Mata, 2005, Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells, Thorax, 60, 144, 10.1136/thx.2004.025692
Matulef, 2003, Cyclic nucleotide-gated ion channels, Annu Rev Cell Dev Biol, 19, 23, 10.1146/annurev.cellbio.19.110701.154854
Maurice, 1990, Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP, Mol Pharmacol, 37, 671
Maxwell, 2004, Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications, Neuroscience, 129, 101, 10.1016/j.neuroscience.2004.07.038
McAllister-Lucas, 1993, The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone, J Biol Chem, 268, 22863, 10.1016/S0021-9258(18)41607-9
McLaughlin, 1993, Low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA, J Biol Chem, 268, 6470, 10.1016/S0021-9258(18)53275-0
McPhee, 1999, Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition, J Biol Chem, 274, 11796, 10.1074/jbc.274.17.11796
Meacci, 1992, Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase, Proc Natl Acad Sci U S A, 89, 3721, 10.1073/pnas.89.9.3721
Mehats, 2002, Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling, Trends Endocrinol Metab, 13, 29, 10.1016/S1043-2760(01)00523-9
Mery, 1995, Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes, Mol Pharmacol, 48, 121
Meyer, 2000, A cGMP-signaling pathway in a subset of olfactory sensory neurons, Proc Natl Acad Sci U S A, 97, 10595, 10.1073/pnas.97.19.10595
Michaeli, 1993, Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae, J Biol Chem, 268, 12925, 10.1016/S0021-9258(18)31474-1
Michibata, 2001, Human Ca2+/calmodulin dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization, Biochim Biophys Acta, 1517, 278, 10.1016/S0167-4781(00)00293-1
Miki, 1975, Purification and properties of the light-activated cyclic nucleotide phosphodiesterase of rod outer segments, J Biol Chem, 250, 6320, 10.1016/S0021-9258(19)41069-7
Miki, 1996, Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family, Genomics, 36, 476, 10.1006/geno.1996.0493
Miot, 1985, Specificity of cGMP binding to a purified cGMP-stimulated phosphodiesterase from bovine adrenal tissue, Eur J Biochem, 149, 59, 10.1111/j.1432-1033.1985.tb08893.x
Miro, 2000, Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-alpha, Biochem Biophys Res Commun, 274, 415, 10.1006/bbrc.2000.3146
Miro, 2001, Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs, Synapse, 40, 201, 10.1002/syn.1043
Miro, 2002, Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study, Neuropharmacology, 43, 1148, 10.1016/S0028-3908(02)00220-4
Miyahara, 1995, Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021, Eur J Pharmacol, 284, 25, 10.1016/0014-2999(95)00355-O
Mongillo, 2004, Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases, Circ Res, 95, 67, 10.1161/01.RES.0000134629.84732.11
Moon, 2003, PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A, Blood, 101, 4122, 10.1182/blood-2002-10-3208
Moos, 1987, Cardiotonic agents: 8. Selective inhibitors of adenosine 3′,5′-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity, J Med Chem, 30, 1963, 10.1021/jm00394a006
Morin, 2001, Expression and role of phosphodiesterase 6 in the chicken pineal gland, J Neurochem, 78, 88, 10.1046/j.1471-4159.2001.00407.x
Mou, 1999, cGMP binding to noncatalytic sites on mammalian rod photoreceptor phosphodiesterase is regulated by binding of its gamma and delta subunits, J Biol Chem, 274, 18813, 10.1074/jbc.274.26.18813
Muller, 1990, Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction, J Cardiovasc Pharmacol, 16, 796, 10.1097/00005344-199011000-00016
Muller, 1990, Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria, J Cardiovasc Pharmacol, 15, 444, 10.1097/00005344-199003000-00015
Muller, 1992, Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles, Eur J Pharmacol, 225, 263, 10.1016/0922-4106(92)90028-T
Muller, 1996, Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition, Trends Pharmacol Sci, 17, 294, 10.1016/0165-6147(96)10035-3
Mullershausen, 2003, Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling, J Cell Biol, 160, 719, 10.1083/jcb.200211041
Muradov, 2004, Structural determinants of the PDE6 GAF A domain for binding the inhibitory gamma-subunit and noncatalytic cGMP, Vision Res, 44, 2437, 10.1016/j.visres.2004.05.013
Murashima, 1990, Characterization of particulate cyclic nucleotide phosphodiesterases from bovine brain: purification of a distinct cGMP-stimulated isoenzyme, Biochemistry, 29, 5285, 10.1021/bi00474a010
Nemoz, 1997, Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid, Mol Pharmacol, 51, 242, 10.1124/mol.51.2.242
Nikulina, 2004, The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery, Proc Natl Acad Sci U S A, 101, 8786, 10.1073/pnas.0402595101
Noguera, 2001, Role of cyclic nucleotide phosphodiesterase isoenzymes in contractile responses of denuded rat aorta related to various Ca2+ sources, Naunyn Schmiedebergs Arch Pharmacol, 363, 612, 10.1007/s002100100397
Nokin, 1989, Amiodarone is a potent calmodulin antagonist, Naunyn Schmiedebergs Arch Pharmacol, 339, 367, 10.1007/BF00736049
Norton, 2000, Mechanism of transducin activation of frog rod photoreceptor phosphodiesterase. Allosteric interactions between the inhibitory gamma subunit and the noncatalytic cGMP-binding sites, J Biol Chem, 275, 38611, 10.1074/jbc.M004606200
O'Connor, 2004, Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific PDE10A phosphodiesterase splice variants, J Biol Chem, 279, 15841, 10.1074/jbc.M312500200
Obernolte, 1993, The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family, Gene, 129, 239, 10.1016/0378-1119(93)90274-7
Oger, 2002, Interleukin-1beta induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3′,5′-monophosphate-dependent pathway, J Clin Endocrinol Metab, 87, 5524, 10.1210/jc.2002-020575
Oki, 2000, Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation, J Biol Chem, 275, 10831, 10.1074/jbc.275.15.10831
Okruhlicova, 1996, Cytochemical distribution of cyclic AMP-dependent 3′,5′-nucleotide phosphodiesterase in the rat myocardium, Histochem J, 28, 165, 10.1007/BF02331440
Okruhlicova, 1997, Species differences in localization of cardiac cAMP-phosphodiesterase activity: a cytochemical study, Mol Cell Biochem, 173, 183, 10.1023/A:1006845513962
Okruhlicova, 1998, Characterization of type 4 cyclic nucleotide phosphodiesterase (PDE4) in cardiac sarcolemma, Exp Clin Cardiol, 3, 188
Onody, 2003, Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study, FEBS Lett, 536, 35, 10.1016/S0014-5793(03)00006-1
Osawa, 2003, Systematic search for single nucleotide polymorphisms in the 5′ flanking region of the human phosphodiesterase 3B gene: absence of evidence for major effects of identified polymorphisms on susceptibility to Japanese type 2 diabetes, Mol Genet Metab, 79, 43, 10.1016/S1096-7192(03)00035-0
Ovchinnikov, 1987, Cyclic GMP phosphodiesterase from bovine retina. Amino acid sequence of the alpha-subunit and nucleotide sequence of the corresponding cDNA, FEBS Lett, 223, 169, 10.1016/0014-5793(87)80530-6
Ovchinnikov, 1986, Cyclic GMP phosphodiesterase from cattle retina. Amino acid sequence of the gamma-subunit and nucleotide sequence of the corresponding cDNA, FEBS Lett, 204, 288, 10.1016/0014-5793(86)80830-4
Owens, 1997, Molecular cloning and expression of a human phosphodiesterase 4C, Cell Signal, 9, 575, 10.1016/S0898-6568(97)00072-7
Pauvert, 2002, Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery, Biochem Pharmacol, 63, 1763, 10.1016/S0006-2952(02)00919-X
Pauvert, 2003, Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery, Br J Pharmacol, 139, 513, 10.1038/sj.bjp.0705277
Piriev, 1995, Gene structure and amino acid sequence of the human cone photoreceptor cGMP-phosphodiesterase alpha' subunit (PDEA2) and its chromosomal localization to 10q24, Genomics, 28, 429, 10.1006/geno.1995.1171
Podzuweit, 1992, Selective inhibition of the cGMP stimulated cyclic nucleotide phosphodiesterase from pig and human myocardium, J Mol Cell Cardiol, 24, S.102, 10.1016/0022-2828(92)90506-U
Podzuweit, 1995, Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine, Cell Signal, 7, 733, 10.1016/0898-6568(95)00042-N
Polli, 1992, Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum, Proc Natl Acad Sci U S A, 89, 11079, 10.1073/pnas.89.22.11079
Prickaerts, 2004, Phosphodiesterase type 5 inhibition improves early memory consolidation of object information, Neurochem Int, 45, 915, 10.1016/j.neuint.2004.03.022
Pugh, 2000, Phototransduction in vertebrate rods and cones: molecular mechanism of amplification, recovery and light adaptation, 183
Pyne, 1986, Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver, Biochem J, 234, 325, 10.1042/bj2340325
Raboisson, 2003, Design, synthesis and structure–activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors, Eur J Med Chem, 38, 199, 10.1016/S0223-5234(02)01446-0
Rahn, 1996, Identification of the site in the cGMP-inhibited phosphodiesterase phosphorylated in adipocytes in response to insulin and isoproterenol, J Biol Chem, 271, 11575, 10.1074/jbc.271.19.11575
Rapoport, 1983, Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP, J Cyclic Nucleotide Protein Phosphor Res, 9, 281
Reed, 2002, Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning, J Neurosci, 22, 5188, 10.1523/JNEUROSCI.22-12-05188.2002
Reeves, 1987, The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors, Biochem J, 241, 535, 10.1042/bj2410535
Reimund, 2001, Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4-inhibiting properties, Biochem Biophys Res Commun, 288, 427, 10.1006/bbrc.2001.5786
Rentero, 2003, Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene, Biochem Biophys Res Commun, 301, 686, 10.1016/S0006-291X(03)00021-4
Richter, 2004, The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases, J Biol Chem, 279, 30338, 10.1074/jbc.M312687200
Rivet-Bastide, 1997, cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes, J Clin Invest, 99, 2710, 10.1172/JCI119460
Robichaud, 2002, Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis, J Clin Invest, 110, 1045, 10.1172/JCI0215506
Rochais, 2004, Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels, J Biol Chem, 279, 52095, 10.1074/jbc.M405697200
Rocque, 1997, Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities, Biochemistry, 36, 14250, 10.1021/bi971112e
Rondinone, 2000, Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor, J Biol Chem, 275, 10093, 10.1074/jbc.275.14.10093
Rosman, 1997, Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3′,5′-cyclic nucleotide phosphodiesterase, Gene, 191, 89, 10.1016/S0378-1119(97)00046-2
Ruppert, 1982, HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro, Life Sci, 31, 2037, 10.1016/0024-3205(82)90095-9
Rybalkin, 2002, Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation, Circ Res, 90, 151, 10.1161/hh0202.104108
Rybalkin, 2003, PDE5 is converted to an activated state upon cGMP binding to the GAF A domain, EMBO J, 22, 469, 10.1093/emboj/cdg051
Sadhu, 1999, Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells, J Histochem Cytochem, 47, 895, 10.1177/002215549904700707
Saeki, 1995, A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery, J Pharmacol Exp Ther, 272, 825
Sarfati, 2003, Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells, Blood, 101, 265, 10.1182/blood-2002-01-0075
Sasaki, 2000, Identification of human PDE7B, a cAMP-specific phosphodiesterase, Biochem Biophys Res Commun, 271, 575, 10.1006/bbrc.2000.2661
Sasaki, 2002, Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation, Biochem J, 361, 211, 10.1042/0264-6021:3610211
Sasaki, 2004, Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons, J Neurochem, 9, 474, 10.1111/j.1471-4159.2004.02354.x
Scapin, 2004, Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity, Biochemistry, 43, 6091, 10.1021/bi049868i
Schneider, 1986, Stereospecific binding of the antidepressant rolipram to brain protein structures, Eur J Pharmacol, 127, 105, 10.1016/0014-2999(86)90210-4
Schoeffter, 1987, Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors, Biochem Pharmacol, 36, 3965, 10.1016/0006-2952(87)90465-5
Schrofner, 2004, Nitric oxide decreases a calcium-activated potassium current via activation of phosphodiesterase 2 in helix U-cells, Brain Res, 999, 98, 10.1016/j.brainres.2003.11.038
Schwabe, 1976, 4-(3-Cyclopentyloxy-4 methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′,5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain, Mol Pharmacol, 12, 900
Sebkhi, 2003, Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension, Circulation, 107, 3230, 10.1161/01.CIR.0000074226.20466.B1
Secchiero, 2000, Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+T cell hyperactivation and HIV type 1 replication, Proc Natl Acad Sci U S A, 97, 14620, 10.1073/pnas.011512398
Senzaki, 2001, Assessment of cardiovascular dynamics by pressure–area relations in pediatric patients with congenital heart disease, J Thorac Cardiovasc Surg, 122, 535, 10.1067/mtc.2001.115424
Sette, 1994, The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation, J Biol Chem, 269, 9245, 10.1016/S0021-9258(17)37100-4
Seybold, 2005, Tumor necrosis factor-α dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability, Blood, 105, 3569, 10.1182/blood-2004-07-2729
Sharma, 1991, Phosphorylation and characterization of bovine heart calmodulin-dependent phosphodiesterase, Biochemistry, 30, 5963, 10.1021/bi00238a021
Sharma, 1985, Differential regulation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase, Proc Natl Acad Sci U S A, 82, 2603, 10.1073/pnas.82.9.2603
Sharma, 1986, Calmodulin and Ca2+-dependent phosphorylation and dephosphorylation of 63-kDa subunit-containing bovine brain calmodulin-stimulated cyclic nucleotide phosphodiesterase isozyme, J Biol Chem, 261, 1322, 10.1016/S0021-9258(17)36094-5
Shimizu-Matsumoto, 1996, Isolation and chromosomal localization of the human cone cGMP phosphodiesterase gamma cDNA (PDE6H), Genomics, 32, 121, 10.1006/geno.1996.0085
Shitsukawa, 2001, Cloning and characterization of the cyclic guanosine monophosphate-inhibited phosphodiesterase PDE3A expressed in mouse oocyte, Biol Reprod, 65, 188, 10.1095/biolreprod65.1.188
Smith, 2003, Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells, Am J Physiol Lung Cell Mol Physiol, 284, L279, 10.1152/ajplung.00170.2002
Smith, 2004, Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+T-lymphocytes, Mol Pharmacol, 66, 1679, 10.1124/mol.104.002246
Snyder, 2005, The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis, J Lipid Res, 46, 494, 10.1194/jlr.M400362-JLR200
Soderling, 2000, Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions, Curr Opin Cell Biol, 12, 174, 10.1016/S0955-0674(99)00073-3
Soderling, 1998, Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases, J Biol Chem, 273, 15553, 10.1074/jbc.273.25.15553
Soderling, 1998, Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase, Proc Natl Acad Sci U S A, 95, 8991, 10.1073/pnas.95.15.8991
Soderling, 1999, Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A, Proc Natl Acad Sci U S A, 96, 7071, 10.1073/pnas.96.12.7071
Sonnenburg, 1991, Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants, J Biol Chem, 266, 17655, 10.1016/S0021-9258(19)47421-8
Sonnenburg, 1995, Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases, J Biol Chem, 270, 30989, 10.1074/jbc.270.52.30989
Sopory, 2003, Modeling and mutational analysis of the GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase, PDE5, FEBS Lett, 539, 161, 10.1016/S0014-5793(03)00219-9
Souness, 1997, Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases, Cell Signal, 9, 227, 10.1016/S0898-6568(96)00173-8
Souness, 1989, Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine, Br J Pharmacol, 98, 725, 10.1111/j.1476-5381.1989.tb14599.x
Souness, 1995, Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram, Br J Pharmacol, 115, 39, 10.1111/j.1476-5381.1995.tb16317.x
Spence, 1997, Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase, Biochem J, 321, 157, 10.1042/bj3210157
Stoclet, 1995, Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases, Expert Opin Investig Drugs, 4, 1081, 10.1517/13543784.4.11.1081
Stryer, 1996, Vision: from photon to perception, Proc Natl Acad Sci U S A, 93, 557, 10.1073/pnas.93.2.557
Sudo, 2000, Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity, Biochem Pharmacol, 59, 347, 10.1016/S0006-2952(99)00346-9
Sullivan, 1994, Molecular cloning and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA, cyclic AMP specific phosphodiesterase (hPDE-IVA-h6.1), Cell Signal, 6, 793, 10.1016/0898-6568(94)00039-5
Sutherland, 1958, Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles, J Biol Chem, 232, 1077, 10.1016/S0021-9258(19)77423-7
Suttorp, 1996, Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability, Am J Physiol, 270, C778, 10.1152/ajpcell.1996.270.3.C778
Swinnen, 1989, Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes, Proc Natl Acad Sci U S A, 86, 5325, 10.1073/pnas.86.14.5325
Swinnen, 1991, Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell, J Biol Chem, 266, 18370, 10.1016/S0021-9258(18)55280-7
Takami, 2005, Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways, FEBS Lett, 579, 832, 10.1016/j.febslet.2004.12.066
Tate, 1998, The gamma-subunit of the rod photoreceptor cGMP-binding cGMP-specific PDE is expressed in mouse lung, Cell Biochem Biophys, 29, 133, 10.1007/BF02737832
Tenor, 1996, Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods, 21
Thomas, 1990, Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase, J Biol Chem, 265, 14964, 10.1016/S0021-9258(18)77210-4
Thompson, 1971, Characterization of cyclic nucleotide phosphodiesterases of rat tissues, J Biol Chem, 246, 3145, 10.1016/S0021-9258(18)62207-0
Torphy, 1991, Phosphodiesterase inhibitors: new opportunities for the treatment of asthma, Thorax, 46, 512, 10.1136/thx.46.7.512
Torphy, 1992, Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast, J Biol Chem, 267, 1798, 10.1016/S0021-9258(18)46016-4
Torphy, 1995, Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists, J Biol Chem, 270, 23598, 10.1074/jbc.270.40.23598
Torras-Llort, 2003, Functional characterization of the human phosphodiesterase 7A1 promoter, Biochem J, 373, 835, 10.1042/bj20021829
Toward, 2005, Airway function and reactivity, leukocyte influx and nitric oxide after inoculation with parainfluenza-3 virus: effects of dexamethasone or rolipram, Int Immunopharmacol, 5, 771, 10.1016/j.intimp.2004.12.006
Tremblay, 1985, Activation of cyclic GMP-binding and cyclic AMP-specific phosphodiesterases of rat platelets by a mechanism involving cyclic AMP-dependent phosphorylation, J Cyclic Nucleotide Protein Phosphor Res, 10, 397
Tsien, 1977, Cyclic AMP and contractile activity in heart, Adv Cycl Nucleotide Res, 8, 363
Turko, 1998, Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation, Biochem J, 329, 505, 10.1042/bj3290505
Udovichenko, 1996, Protein kinase C in rod outer segments: effects of phosphorylation of the phosphodiesterase inhibitory subunit, Biochem J, 317, 291, 10.1042/bj3170291
Van Staveren, 2002, Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain, J Neurocytol, 31, 729, 10.1023/A:1025704031210
Van Staveren, 2003, mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain, J Comp Neurol, 467, 566, 10.1002/cne.10955
Van Staveren, 2004, Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry, Eur J Neurosci, 19, 2155, 10.1111/j.0953-816X.2004.03327.x
Vandecasteele, 2001, Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes, J Physiol, 533, 329, 10.1111/j.1469-7793.2001.0329a.x
Vemulapalli, 1996, Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor, J Cardiovasc Pharmacol, 28, 862, 10.1097/00005344-199612000-00018
Verde, 2001, Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase, J Biol Chem, 276, 11189, 10.1074/jbc.M006546200
Vergne, 2004, Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors: Part 2. Metabolism-directed optimization studies towards orally bioavailable derivatives, Bioorg Med Chem Lett, 14, 4615, 10.1016/j.bmcl.2004.07.009
Vo, 1998, Identification of cGMP-dependent protein kinase anchoring proteins (GKAPs), Biochem Biophys Res Commun, 246, 831, 10.1006/bbrc.1998.8722
Waki, 1999, Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models, Jpn J Pharmacol, 79, 477, 10.1254/jjp.79.477
Wang, 1990, Calmodulin-stimulated cyclic nucleotide phospohdiesterases, 19
Wang, 2000, Cloning, characterization, and tissue distribution of mouse phosphodiesterase 7A1, Biochem Biophys Res Commun, 276, 1271, 10.1006/bbrc.2000.3613
Wang, 2001, Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution, Gene, 280, 183, 10.1016/S0378-1119(01)00783-1
Wang, 2003, Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants, Gene, 314, 15, 10.1016/S0378-1119(03)00733-9
Wechsler, 2002, Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes, J Biol Chem, 277, 38072, 10.1074/jbc.M203647200
Weeks, 2005, High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients, Int J Impot Res, 17, 5, 10.1038/sj.ijir.3901283
Weishaar, 1987, Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility, Circ Res, 61, 539, 10.1161/01.RES.61.4.539
Wells, 1975, Cyclic nucleotide phosphodiesterase activities of pig coronary arteries, Biochim Biophys Acta, 384, 430, 10.1016/0005-2744(75)90044-3
Whalin, 1988, Purification and partial characterization of membrane-associated type II (cGMP-activatable) cyclic nucleotide phosphodiesterase from rabbit brain, Biochim Biophys Acta, 972, 79, 10.1016/0167-4889(88)90105-X
Wong, 2004, AKAP signalling complexes: focal points in space and time, Nat Rev Mol Cell Biol, 5, 959, 10.1038/nrm1527
Wu, 2001, Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells, Biochem Pharmacol, 61, 877, 10.1016/S0006-2952(01)00553-6
Wu, 2004, Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A, J Biol Chem, 279, 37928, 10.1074/jbc.M404287200
Xu, 2000, Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity, Science, 288, 1822, 10.1126/science.288.5472.1822
Xu, 2004, Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram, J Mol Biol, 337, 355, 10.1016/j.jmb.2004.01.040
Yamaguchi, 1998, E 4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats, Nihon Kokyuki Gakkai Zasshi, 36, 23
Yamamoto, 1983, Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase, J Biol Chem, 258, 14173, 10.1016/S0021-9258(17)43840-3
Yamazaki, 2002, Binding of cGMP to GAF domains in amphibian rod photoreceptor cGMP phosphodiesterase (PDE). Identification of GAF domains in PDE alphabeta subunits and distinct domains in the PDE gamma subunit involved in stimulation of cGMP binding to GAF domains, J Biol Chem, 277, 40675, 10.1074/jbc.M203469200
Yan, 1995, Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons, Proc Natl Acad Sci U S A, 92, 9677, 10.1073/pnas.92.21.9677
Yan, 1996, The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner, J Biol Chem, 271, 25699, 10.1074/jbc.271.41.25699
Yan, 2001, Stage and cell-specific expression of calmodulin-dependent phosphodiesterases in mouse testis, Biol Reprod, 64, 1746, 10.1095/biolreprod64.6.1746
Yanaka, 2003, CGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles, Biosci Biochem, 67, 973, 10.1271/bbb.67.973
Yang, 1994, A novel cyclic GMP stimulated phosphodiesterase from rat brain, Biochem Biophys Res Commun, 205, 1850, 10.1006/bbrc.1994.2886
Yang, 2003, Phosphodiesterase 7A-deficient mice have functional T cells, J Immunol, 171, 6414, 10.4049/jimmunol.171.12.6414
Yu, 1997, Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1, Cell Signal, 9, 519, 10.1016/S0898-6568(97)00046-6
Yuasa, 2000, Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression, J Biol Chem, 275, 31469, 10.1074/jbc.M003041200
Yuasa, 2001, Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): comparison of rat and human PDE11A splicing variants, Eur J Biochem, 268, 4440, 10.1046/j.1432-1327.2001.02366.x
Zhang, 2002, Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme, Neuropsychopharmacology, 27, 587
Zhang, 2002, Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats, Stroke, 33, 2675, 10.1161/01.STR.0000034399.95249.59
Zhao, 1998, Leptin inhibits insulin secretion by activation of phosphodiesterase 3B, J Clin Invest, 102, 869, 10.1172/JCI3920
Zhao, 2002, A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding, Nat Neurosci, 5, 727, 10.1038/nn885